Trial Profile

A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin degludec/insulin aspart (Primary) ; Insulin glargine
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms BOOST; BOOST-START-1
Sponsors Novo Nordisk

Most Recent Events

11 Sep 2013 Planned number of patients changed from 526 to 752 as reported by European Clinical Trials Database record.
11 Sep 2013 Planned number of patients changed from 526 to 752 as reported by European Clinical Trials Database record.
07 Feb 2011 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com